查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1888753

美國白血病藥物市場規模、佔有率和趨勢分析報告：按類型、治療方法、分銷管道和細分市場預測（2025-2033 年）

U.S. Leukemia Therapeutics Market Size, Share & Trends Analysis Report By Type (Chronic Myeloid Leukemia (CML), Chronic Lymphocytic Leukemia (CLL)), By Treatment, By Distribution Channels, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

美國白血病藥物市場摘要

據估計，2024年美國白血病藥物市值為72.3億美元，預計到2033年將達到130.7億美元。

預計從 2025 年到 2033 年，該行業將以 6.80% 的複合年成長率成長。標靶治療因其臨床精準度高而日益普及，這是推動該行業成長的主要因素。

基因組分析技術的廣泛應用有助於精準選擇治療方法，並提升整體治療效果。 CAR-T細胞療法的日益普及，透過提高高風險患者的緩解期持久性，推動了市場成長。雙特異性抗體的進步也為復發和難治性病例提供了更多治療選擇。例如，根據美國國家癌症研究所（透過監測、流行病學和最終結果計畫）2024年3月發布的報告，截至2022年，美國預計將有536,245名白血病患者，顯示該疾病的盛行率很高。分子診斷技術的廣泛應用有助於識別適合接受先進治療方法的患者。新一代藥物的持續研發也維持了市場成長動能。人們對個人化癌症治療日益成長的需求，預計將進一步增強對治療的長期需求。

隨著臨床研發管線為急性和慢性白血病提供新的作用機制，治療方法推動了市場成長。口服標靶藥物的日益普及提高了患者的依從性，從而支撐了強勁的商業性表現。不斷擴大的臨床證據增強了主要腫瘤醫療網路中處方醫生的信心。存活率的提高帶來了維持治療和後續治療的持續需求。人口老化帶來的高疾病負擔推動了多種類型白血病治療的啟動。聯合治療的進展提高了治療第一線和挽救治療的療效深度。例如，根據 Business Wire 報告，2025 年 11 月，美國食品藥物管理局(FDA) 授予 Leukogene Therapeutics Inc. 的主要候選產品 LTI-214（也稱為 M2T-CD33）孤兒藥資格，用於治療急性骨髓性白血病(AML)。這為合格的臨床試驗費用核准了稅額扣抵，免除了部分 FDA 費用，並在核准後享有美國市場獨佔權。大型製藥企業的積極投資正在加速新藥的研發和商業化。

美國癌症專科治療中心的普及提高了患者獲得治療的機會，促進了市場擴張。真實世界數據（RWE）的累積推動了免疫療法和標靶治療的廣泛應用。高價值生物製劑的利用率不斷提高，增強了主要製藥廠商的收入貢獻。治療反應持久性的增加降低了復發率，並有助於長期持續治療。主要癌症機構臨床試驗活動的活性化，促進了新興治療平台的快速評估。對精準治療路徑的日益重視，推動了先進療法的穩定應用。患者管理方法的不斷改進，增強了對白血病治療的持續需求。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章美國白血病藥物市場變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章美國白血病藥物市場：按類型分類的業務分析

  • 按類型分類的市場佔有率（2024 年和 2033 年）
  • 按類型分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 慢性骨髓性白血病（CML）
  • 慢性淋巴性白血病（CLL）
  • 急性淋巴性白血病（ALL）
  • 急性骨髓性白血病（AML）
  • 其他

第5章美國白血病藥物市場：按療法分類的業務分析

  • 按療法分類的市場佔有率（2024 年和 2033 年）
  • 按治療方法分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 化療
  • 標靶治療
  • 免疫療法
  • 其他

第6章美國白血病藥物市場：按分銷管道分類的業務分析

  • 按分銷管道分類的市場佔有率（2024 年和 2033 年）
  • 按分銷管道分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 醫院藥房
  • 零售藥房
  • 其他

第7章 競爭情勢

  • 參與公司概況
  • 企業市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/列表
    • Novartis
    • Roche/Genentech
    • AbbVie
    • Bristol-Myers Squibb（BMS）
    • Pfizer
    • Amgen
    • Johnson &Johnson（Janssen）
    • Gilead Sciences（Kite Pharma）
    • AstraZeneca
    • Sanofi
Product Code: GVR-4-68040-808-9

U.S. Leukemia Therapeutics Market Summary

The U.S. leukemia therapeutics market size was estimated at USD 7.23 billion in 2024 and is projected to reach USD 13.07 billion by 2033, growing at a CAGR of 6.80% from 2025 to 2033. The industry is expanding due to the strong adoption of targeted therapies that offer high clinical precision.

Increased use of genomic profiling supports accurate treatment selection and enhances overall therapeutic outcomes. Growth in CAR-T cell therapy utilization adds momentum through improved remission durability in high-risk patients. Advancements in bispecific antibodies strengthen options for relapsed and refractory cases. For instance, in March 2024, the National Cancer Institute (via the Surveillance, Epidemiology, and End Results Program) reported that in the U.S., there were an estimated 536,245 people living with leukemia in 2022, representing the prevalence of the disease. The broader integration of molecular diagnostics enhances patient identification for advanced therapies. Continuous development of next-generation agents sustains momentum in the market. The rising preference for personalized oncology care is expected to strengthen long-term treatment demand.

Therapeutic innovation strengthens market growth as clinical pipelines deliver novel mechanisms for acute and chronic leukemia. Wider availability of oral targeted agents improves adherence and supports strong commercial performance. Expansion of clinical evidence enhances prescriber confidence across major oncology networks. Increased survival rates create ongoing demand for maintenance and follow-up therapies. High disease burden within aging populations drives treatment initiation across multiple leukemia types. Advancements in combination regimens have improved the depth of response in both frontline and salvage settings. For instance, in November 2025, Business Wire reported that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Leukogene Therapeutics Inc.'s lead product candidate LTI-214 (also named M2T-CD33) for the treatment of Acute Myeloid Leukemia (AML), providing incentives such as tax credits on qualified clinical trial costs, waiver of certain FDA fees, and U.S. market exclusivity upon approval. Strong investment from major pharmaceutical companies accelerates the development and commercialization of new agents.

Improved treatment access through specialized oncology centers contributes to market expansion across the U.S. Growth in real-world evidence supports broader adoption of immunotherapy and targeted strategies. Higher utilization of high-value biologics strengthens revenue contribution across leading manufacturers. Enhanced therapeutic durability reduces the frequency of relapse and encourages continued long-term therapy. Rising clinical trial activity in major cancer institutions supports rapid evaluation of emerging platforms. An increased emphasis on precision treatment pathways supports the consistent uptake of advanced therapeutics. Continuous improvements in patient management practices reinforce sustained demand for leukemia treatments.

U.S. Leukemia Therapeutics Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. leukemia therapeutics market report based on type, treatment, and distribution channels:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Chronic Myeloid Leukemia (CML)
  • Chronic Lymphocytic Leukemia (CLL)
  • Acute Lymphocytic Leukemia (ALL)
  • Acute Myeloid Leukemia (AML)
  • Others
  • Treatment Outlook (Revenue, USD Million, 2021 - 2033)
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Others
  • Distribution Channels Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Treatment
    • 1.2.3. Distribution Channels
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Leukemia Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. U.S. Leukemia Therapeutics Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2033
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.4. Chronic Myeloid Leukemia (CML)
    • 4.4.1. Chronic Myeloid Leukemia (CML) Market, 2021 - 2033 (USD Million)
  • 4.5. Chronic Lymphocytic Leukemia (CLL)
    • 4.5.1. Chronic Lymphocytic Leukemia (CLL) Market, 2021 - 2033 (USD Million)
  • 4.6. Acute Lymphocytic Leukemia (ALL)
    • 4.6.1. Acute Lymphocytic Leukemia (ALL) Market, 2021 - 2033 (USD Million)
  • 4.7. Acute Myeloid Leukemia (AML)
    • 4.7.1. Acute Myeloid Leukemia (AML) Market, 2021 - 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. U.S. Leukemia Therapeutics Market: Treatment Business Analysis

  • 5.1. Treatment Market Share, 2024 & 2033
  • 5.2. Treatment Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by treatment, 2021 to 2033 (USD Million)
  • 5.4. Chemotherapy
    • 5.4.1. Chemotherapy Market, 2021 - 2033 (USD Million)
  • 5.5. Targeted Therapy
    • 5.5.1. Targeted Therapy Market, 2021 - 2033 (USD Million)
  • 5.6. Immunotherapy
    • 5.6.1. Immunotherapy Market, 2021 - 2033 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. U.S. Leukemia Therapeutics Market: Distribution Channels Business Analysis

  • 6.1. Distribution Channels Market Share, 2024 & 2033
  • 6.2. Distribution Channels Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by distribution channels, 2021 to 2033 (USD Million)
  • 6.4. Hospital Pharmacy
    • 6.4.1. Hospital Pharmacy Market, 2021 - 2033 (USD Million)
  • 6.5. Retail Pharmacy
    • 6.5.1. Retail Pharmacy Market, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Novartis
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Roche / Genentech
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. AbbVie
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Bristol-Myers Squibb (BMS)
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Pfizer
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Amgen
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Johnson & Johnson (Janssen)
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Gilead Sciences (Kite Pharma)
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. AstraZeneca
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Sanofi
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. leukemia therapeutics market, by Type, 2021-2033, (USD Million)
  • Table 4 U.S. leukemia therapeutics market, by treatment, 2021-2033, (USD Million)
  • Table 5 U.S. leukemia therapeutics market, by distribution channels, 2021-2033, (USD Million)

List of Figures

  • Fig. 1 U.S. leukemia therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 U.S. leukemia therapeutics market dynamics
  • Fig. 12 U.S. leukemia therapeutics market: Porter's five forces analysis
  • Fig. 13 U.S. leukemia therapeutics market: PESTLE analysis
  • Fig. 14 Type market, 2021 - 2033 (USD Million)
  • Fig. 15 Chronic Myeloid Leukemia (CML) market, 2021 - 2033 (USD Million)
  • Fig. 16 Chronic Lymphocytic Leukemia (CLL) market, 2021 - 2033 (USD Million)
  • Fig. 17 Acute Lymphocytic Leukemia (ALL) market, 2021 - 2033 (USD Million)
  • Fig. 18 Acute Myeloid Leukemia (AML) market, 2021 - 2033 (USD Million)
  • Fig. 19 Others market, 2021 - 2033 (USD Million)
  • Fig. 20 Treatment market, 2021 - 2033 (USD Million)
  • Fig. 21 Chemotherapy market, 2021 - 2033 (USD Million)
  • Fig. 22 Targeted Therapy market, 2021 - 2033 (USD Million)
  • Fig. 23 Immunotherapy market, 2021 - 2033 (USD Million)
  • Fig. 24 Others market, 2021 - 2033 (USD Million)
  • Fig. 25 Distribution Channels market, 2021 - 2033 (USD Million)
  • Fig. 26 Hospital Pharmacy market, 2021 - 2033 (USD Million)
  • Fig. 27 Retail Pharmacy market, 2021 - 2033 (USD Million)
  • Fig. 28 Others market, 2021 - 2033 (USD Million)
  • Fig. 29 Company categorization
  • Fig. 30 Company market position analysis
  • Fig. 31 Strategic framework